(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kate Hudson, 46, says she doesn't need long workouts to feel good - 25 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- 3Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- 4Manual for Wonderful Getaway destination
- 5Vote In favor of Your Favored Web based Dating Application
- Building a Flourishing Business: Illustrations from Business people
- Israeli president concerned over proposed renaming of park
- Bombardier Global 8000 Enters Service
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Find Exemplary Scents: An Extensive Aide
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
